Evommune to present Phase 2a EVO301 atopic dermatitis data at EADV 2026 late-breaker session
Bitget2026/09/23 20:06- Evommune set a late-breaking oral presentation of Phase 2a EVO301 data in moderate-to-severe atopic dermatitis at EADV 2026.
- Results were already disclosed as positive top-line findings earlier in 2026; full data will be presented on Oct. 1 in Vienna.
- Readout supports IL-18 inhibition as a potential new approach in atopic dermatitis, targeting broader inflammatory pathways than Th2-focused therapies.
- Phase 2b dose-ranging study is expected to start in mid-2027, setting up the next development step for EVO301.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
